接受BRCA检测的美国卵巢癌患者的实际治疗模式和护理成本
Srujitha Marupuru1, Kristin Moore2, Desiree Hall2
1Merck.
Journal of health economics and outcomes research
|September 2, 2025
概括
接受BRCA检测的卵巢癌患者的医疗费用显著增加,主要是因门诊诊所的增加和针对性治疗的药房费用增加. 在测试获取方面也存在差异.
科学领域:
- 癌症学
- 基因组学
- 健康经济学
背景情况:
- 卵巢癌患者面临巨大的经济负担.
- 关于治疗模式,医疗资源利用 (HCRU) 和区分BRCA突变 (BRCAm) 和BRCA野生型 (BRCAwt) 瘤的成本的了解有限.
研究的目的:
- 评估人口和临床特征.
- 评估卵巢癌患者的治疗模式,HCRU和成本.
- 根据BRCA测试状态和结果对分析进行分层.
主要方法:
- 对卵巢癌患者的回顾性研究 (2017年1月至2022年6月).
- 使用电子健康记录和行政索赔数据.
- 收集了基线特征,治疗线 (LOT),HCRU和成本的数据;通过BRCA测试和结果分层.
主要成果:
- 包括13,981名患者;其中23. 3%接受了BRCA检测.
- 接受BRCA检测的患者更有可能接受随后的LOT和BRCA向治疗.
- 在BRCA检测的患者中,平均每月每病人 (PPPM) 总费用高出62%,主要原因是门诊诊所 (81%高) 和药房费用 (137%高).
结论:
- 大约四分之一的卵巢癌患者接受了BRCA检测,观察到差异.
- 与未经检测的患者相比,BRCA检测患者的医疗费用更高.
- 试验患者的成本增加主要是由于门诊和药房费用增加,这可能与向治疗有关.
更多相关视频
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
7.4K
08:15gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair
Published on: October 6, 2014
12.3K
相关概念视频
Cancer Survival Analysis
448
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
448
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
